
Roger McIntyre
Professor in the Departments of Psychiatry and Pharmacology at the University of Toronto and CEO of Braxia Scientific Corp. His research focuses on treatment-resistant depression and bipolar disorder.
Top 3 podcasts with Roger McIntyre
Ranked by the Snipd community

8 snips
Jan 18, 2024 • 48min
2.8 Depressive Disorders
Dr. Roger McIntyre, Professor of Psychiatry at the University of Toronto, discusses the differentiation of normal 'low mood' from psychiatric conditions. The podcast covers historical subtypes of depression, DSM specifiers for major depressive disorder, epidemiology, neurophysiology, and treatment options.

5 snips
Nov 13, 2024 • 1h 2min
E240 - 2024 NEI Congress Extended Q&A with Dr. Katherine Dahlsgaard, Dr. Roger McIntyre, Dr. Thomas Schwartz, and Lisa Tremayne
Join Dr. Katherine Dahlsgaard, an expert in child social anxiety, as she shares innovative strategies like cognitive behavioral therapy for pediatric patients. Dr. Roger McIntyre discusses the fascinating link between inflammation, diet, and mental health, emphasizing the importance of nutrition in treating depression. Dr. Thomas Schwartz provides insights on sleep disorders, highlighting effective use of caffeine and melatonin for better rest. Together, they tackle vital topics that intertwine mental health, childhood anxiety, and lifestyle choices.

Mar 26, 2025 • 59min
E251 - (CME) Prescribing Potentially Unsafe Drug Combinations in Treatment-Resistant Cases
Dr. Roger S. McIntyre, a leading expert in treatment-resistant depression and bipolar disorder, joins Dr. Andrew Cutler to discuss the complexities of prescribing potentially unsafe drug combinations. They explore the intricacies of pharmacokinetics and pharmacodynamics, emphasizing the risks of polypharmacy. Key topics include the importance of monitoring drug interactions, the implications of anticholinergic medications, and the safety of stimulants in mood disorders. The conversation highlights guidelines for responsible prescribing and the challenges of managing treatment-resistant cases.